{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:20:17Z","timestamp":1789129217035,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prognosis of adult patients with relapsed\/refractory (r\/r) or measurable residual disease (MRD)\u2013positive B-precursor acute lymphoblastic leukemia (B-ALL) remains poor. Blinatumomab induces complete remissions (CR) and MRD negativity in a subset of patients, yet overall survival remains limited. As BCL2 overexpression contributes to leukemic cell survival and therapy resistance, combining Blinatumomab with the BCL2 inhibitor Venetoclax may enhance therapeutic efficacy. The GMALL-BLIVEN (NCT05182385) phase I multicenter trial evaluated the safety and feasibility of Venetoclax plus Blinatumomab in adults with CD19\u207a, Philadelphia chromosome\u2013negative r\/r or MRD-positive B-ALL. Dose escalation followed a 3\u2009+\u20093 design across three Venetoclax dose levels (DL-1: 400 mg; DL-2: 600 mg; DL-3: 800 mg) administered from day \u2212\u20097 to day 42, with Blinatumomab given per label. The primary endpoint was determination of the maximum tolerated dose (MTD); key secondary endpoint was achievement of molecular complete remission (MOL-CR) by centralized IG\/TR MRD assessment (sensitivity\u2009\u2265\u200910\u207b\u2074). Nine patients (median age 52 years, range 22\u201371) were enrolled across four German centers: four with r\/r B-ALL and five with MRD-positive disease. Molecular subtypes included ZNF384-rearranged (n\u2009=\u20092), BCR::ABL1-like (n\u2009=\u20092), CEBP-rearranged (n\u2009=\u20091), hypodiploidy (n\u2009=\u20091), B-ALL NOS (n\u2009=\u20092), and KMT2A-rearranged (n\u2009=\u20091). No dose-limiting toxicities were observed, and the MTD was not reached. Treatment-emergent grade\u2009\u2265\u2009III toxicities included neutropenia, febrile neutropenia, cytokine release syndrome, and ICANS; no 30- or 60-day mortality occurred. Six patients completed two full cycles without treatment interruptions. The recommended phase II dose (RP2D) was established as Venetoclax 800 mg daily plus standard-dose Blinatumomab. All nine patients were evaluable for response. Among r\/r B-ALL, responses included PR (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091), CR (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091), and PD (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092). Among MRD-positive patients, 4\/5 achieved MOL-CR. Four patients were successfully bridged to allogeneic stem cell transplantation. After a median follow-up of 17.8 months, median overall survival was 15.0 months (r\/r: 6.6 months; MRD-positive: 16.9 months). Non-responders were enriched for adverse molecular subtypes (BCR::ABL1-like and hypodiploid B-ALL). Venetoclax combined with Blinatumomab is safe and feasible in adults with r\/r or MRD-positive B-ALL, without increased rates of CRS or neurotoxicity compared with Blinatumomab alone. High rates of MRD clearance were observed in MRD-positive patients. The phase II portion of GMALL-BLIVEN is ongoing at the RP2D of Venetoclax 800 mg daily.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06883-8","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T01:11:10Z","timestamp":1770858670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Venetoclax and Blinatumomab for adult patients with relapsed\/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial"],"prefix":"10.1007","volume":"105","author":[{"given":"Lars","family":"Fransecky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Raffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Heberling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Steer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Versteegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Spory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Deckbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bendig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Beder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"9","key":"6883_CR1","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"14","key":"6883_CR2","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"issue":"14","key":"6883_CR3","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1073\/pnas.83.14.5214","volume":"83","author":"Y Tsujimoto","year":"1986","unstructured":"Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83(14):5214\u20135218","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1\u20132","key":"6883_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1083\/jcb.124.1.1","volume":"124","author":"JC Reed","year":"1994","unstructured":"Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124(1\u20132):1\u20136","journal-title":"J Cell Biol"},{"issue":"4","key":"6883_CR5","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","volume":"111","author":"V Del Gaizo Moore","year":"2008","unstructured":"Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111(4):2300\u20132309","journal-title":"Blood"},{"issue":"2","key":"6883_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1046\/j.1365-2141.2002.03637.x","volume":"118","author":"M Konopleva","year":"2002","unstructured":"Konopleva M, Zhao S, Hu W et al (2002) The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34\u2009+\u2009cells. Br J Haematol 118(2):521\u2013534","journal-title":"Br J Haematol"},{"issue":"11","key":"6883_CR7","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos L, Rouault JP, Sabido O et al (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81(11):3091\u20133096","journal-title":"Blood"},{"issue":"5","key":"6883_CR8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.24862","volume":"116","author":"S Faderl","year":"2010","unstructured":"Faderl S, O\u2019Brien S, Pui CH et al (2010) Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116(5):1165\u20131176","journal-title":"Cancer"},{"issue":"10","key":"6883_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A (2018) BCL-2 Inhibition in AML: an unexpected bonus? Blood 132(10):1007\u20131012","journal-title":"Blood"},{"issue":"2","key":"6883_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202\u2013208","journal-title":"Nat Med"},{"issue":"11","key":"6883_CR11","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V, Dobay MP, Rinaldi A et al (2017) Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129(11):e26\u2013e37","journal-title":"Blood"},{"key":"6883_CR12","doi-asserted-by":"publisher","unstructured":"NumanY, Alfayez M, Maiti A et al (2018) First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol 2:1\u201362. https:\/\/doi.org\/10.1200\/PO.18.00127","DOI":"10.1200\/PO.18.00127"},{"issue":"6","key":"6883_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E et al (2021) Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453","journal-title":"Cancer Discov"},{"issue":"4","key":"6883_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N et al (2024) A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909\u2013915","journal-title":"Blood Adv"},{"issue":"9","key":"6883_CR15","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1097\/HS9.0000000000000939","volume":"7","author":"T Beder","year":"2023","unstructured":"Beder T, Hansen BT, Hartmann AM et al (2023) The gene expression classifier allcatchr identifies B-cell precursor ALL subtypes and underlying developmental trajectories across age. HemaSphere 7(9):e939","journal-title":"HemaSphere"},{"key":"6883_CR16","doi-asserted-by":"crossref","unstructured":"Horns JM, Beder T, Br\u00fcggemann M (2024) IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma. ASH Annual Meeting and Exposition. San Diego, CA","DOI":"10.1182\/blood-2024-199601"},{"issue":"13","key":"6883_CR17","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML et al (2022) Impact of venetoclax and Azacitidine in Treatment-Naive patients with acute myeloid leukemia and IDH1\/2 mutations. Clin Cancer Research: Official J Am Association Cancer Res 28(13):2753\u20132761","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06883-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:07:04Z","timestamp":1781633224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06883-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6883"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06883-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by AbbVie Inc. Some authors have received grants, consulting fees, or speaker honoraria from this company; others have no conflicts to declare. A detailed list of individual author disclosures is as follows: LF has received consulting fees and travel support from AbbVie. LF has received consulting fees from Amgen. LB, TB, LR, DD, CB, SR, WA, KH, TV, LS, BS, SB and MN have nothing to disclose. NG received institutional grants and speaker fees from Amgen during the conduct of the study, and has served on advisory boards for Amgen. NG has also received research funding to support the submitted work. MB received travel support, research grants, speaker and consulting fees from Amgen during the conduct of this study. WF has received speaker fees and travel support from Amgen and AbbVie. CR has received honoraria and institutional research funding from AbbVie. TS has received honoraria and speaker fees from AbbVie. LH has received consulting fees from Amgen and travel support from Amgen and Abbvie. CBD has received consulting fees for Amgen and grants from AbbVie during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}